Global Viral Vector And Plasmid Overview
Introduction:
Viral vectors and plasmid DNA are used in gene therapy. It is used to treat various diseases, such as Parkinson's disease, Alzheimer's disease, cancer, and other diseases. Gene therapies and other therapies that need genetic modification include the introduction of therapeutic DNA/gene in the patient's cell or body. This process is proficient by the use of viral vectors. In the past few years, different non-viral and viral vectors have been standardized and developed for the treatment purpose. Besides this, the viral vectors and plasmid DNAs are anticipated to decrease the repetitive administration of medications.
Global Viral Vector And Plasmid Dynamics
The increasing number of cancer patients drives the growth of the global viral vector and plasmid DNA manufacturing market globally. Viral vectors and plasmid DNA are used to treat diseases such as cancer and various other diseases globally. For instance, according to the WHO (World Health Organization), in 2018, globally, cancer is the second most leading cause of death, an estimated 9.6 million deaths. Additionally, the technological advancement in the production of a viral vector to take care of patients which are another driving factor for the growth of the target market. Furthermore, the rise in the number of clinical trials of viral vector and plasmid DNA for better treatment is the fueling factor for the growth of the global market. Moreover, there is the rapid development of clinical trial phases due to growing numbers of candidates for the use of viral vector and plasmid DNA which is the boosting factor for the growth of the target market. However, the gene therapies are expensive treatment which is the major restraining factor for the growth of the target market.
Global Viral Vector And Plasmid Segmentation
The global viral vector and plasmid DNA manufacturing market are segmented based on product type, application, and region.
Based on product type, the global viral vector and plasmid DNA manufacturing market are segmented into plasmid DNA, viral vectors, and non-viral vectors. The viral vectors are estimated the more revenue generator in the target market. Based on the application, the target market is segmented into cancer, inherited disorder, infectious diseases, and other applications. As there is an increasing number of cancer patients, cancer is the dominating segment for the growth of the global market.
Regional Insights:
Based on the region the global viral vector and plasmid DNA manufacturing market are segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in the North America region is seen to have a matured growth since this market correlates with the increasing growth rate of viral vector and plasmid DNA manufacturing. In the North America region, the increasing awareness about gene therapy is driving the growth of the global market in this region. Moreover, investments into research and development for better healthcare is anticipated to create growth opportunities for the Europe region viral vector and plasmid DNA manufacturing market over the forecast period.
Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
- Plasmid DNA
- Viral Vectors
- Non-viral vectors
Global Viral Vector and Plasmid DNA Manufacturing Market, By Application:
- Cancer
- Inherited Disorder
- Infectious Diseases
- Other Applications
Global Viral Vector and Plasmid DNA Manufacturing Market, By Region:
- North America
- North America Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
- North America Viral Vector and Plasmid DNA Manufacturing Market, By Application
- North America Viral Vector and Plasmid DNA Manufacturing Market, By Country
- The U.S.
- Canada
- Europe
- Europe Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
- Europe Viral Vector and Plasmid DNA Manufacturing Market, By Application
- Europe Viral Vector and Plasmid DNA Manufacturing Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
- Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Application
- Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
- Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Application
- Latin America Viral Vector and Plasmid DNA Manufacturing Market, By Country
-
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Product Type
- Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Application
- Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, By Country
-
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
-
Global Viral Vector And Plasmid Key Players
The key players operating the global viral vector and plasmid DNA manufacturing market involves Unique NV, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies), Mass Biologics, SIRION Biotech, Cobra Biologics, Merck KGaA, Oxford Biomedica PLC, Thermo Fisher Scientific Inc. and Gilead Company. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the product types to gain a competitive edge in the target market. In 2017, the retrovirus- based CAR-T cell immunotherapy developed in Gilead Company, was approved by the FDA.
Global Viral Vector And Plasmid Company Profile
- Uniqure NV *
- Company Overview
- Product Type Portfolio
- Key Highlights
- Financial Performance
- Cell and Gene Therapy Catapult
- FinVector Vision Therapies
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- MassBiologics
- SIRION Biotech
- Cobro Biologics
- Merck KGaA
- Oxford Biomedica PLC
- Thermo Fisher Scientific Inc.
- Gilead Company
“*” marked represents similar segmentation in other categories in the respective section
Global Viral Vector And Plasmid Table of Contents
Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Industry Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Viral Vector and Plasmid DNA Manufacturing Strategies
- Key Questions this Study will Answer
- Market Snippet, By Product Type
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Plasmid DNA
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Viral Vectors
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Non- viral Vectors
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Cancer
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Inherited Disorder
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Infectious Diseases
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Other Applications
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- 3D Systems *
-
- Company Overview
-
- 3D Systems *
-
-
-
- Product Type Portfolio
- Key Highlights
- Financial Performance
-
- CAE Inc.
- Intuitive Surgical, Inc.
- Mentice AB
- Mimic Technologies, Inc.
- Simulated Surgical Systems, LLC
- Touch of Life Technologies (ToLTech)
- VirtaMed AG
- Voxel- Man
- VRmagic
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global viral vector and plasmid DNA manufacturing market are segmented based on product type, application, and region.
The increasing number of cancer patients drives the growth of the global viral vector and plasmid DNA manufacturing market globally.
The global market in the North America region is seen to have a matured growth since this market correlates with the increasing growth rate of viral vector and plasmid DNA manufacturing.
Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the product types to gain a competitive edge in the target market. In 2017, the retrovirus- based CAR-T cell immunotherapy developed in Gilead Company, was approved by the FDA.